R-191

R-191 is an investigational **small-molecule IRAK-4 inhibitor** being explored for hematologic cancers, particularly acute myeloid leukemia and related hematological malignancies. It is designed to inhibit **interleukin-1 receptor-associated kinase 4**, a signaling kinase downstream of the **Toll-like receptor** and **interleukin-1 receptor** pathways, thereby suppressing pro-inflammatory cytokine production in primary cells. Preclinical reports also indicate that R-191 can reduce **PD-L1 expression** in acute myeloid leukemia cell lines, supporting a potential antitumor immunomodulatory and targeted antineoplastic role. Based on the provided context, the program appears to remain in the **research or discovery-stage**, with limited public disclosure regarding a definitive commercial developer, manufacturer, brand name, formulation, or clinical trial progression.